Research News

Bimekizumab is a first-of-its-kind dual IL-17 inhibitor that targets both IL-17A and…

The U.S. FDA has approved a new medication to treat…

SAA is rolling out two accredited continuing education programs to…

Researchers at the University of Toronto in Ontario, Canada have uncovered a…

The FDA has approved the first interchangeable biosimilar for adalimumab (Humira), a TNF inhibitor commonly taken for spondyloarthritis…

Among adults with rheumatic diseases including spondyloarthritis, who received COVID-19…